Measuring rates of brain atrophy from serial magnetic resonance imaging (MRI) scans is gaining acceptance as a valid noninvasive biomarker of disease progression in neurodegenerative conditions. To date, the two most widely used measurement techniques are, manual segmentation of specific structures (e.g. hippocampus), or semi-automated image registration and subtraction to generate whole brain atrophy rates. Both of these techniques, while useful, have important limitations in neurodegenerative conditions that are characterized by atrophy of select regions of the brain. A prototypical neurodegenerative condition that is characterized by selective atrophy is frontal temporal dementia (FTD). A class of computational techniques that we refer to in this application as tensor based morphometry (TBM) seem ideally suited to measure atrophy rates of defined regions/lobes of the brain from serial MRI scans. We have developed a prototype version of a TBM algorithm and the associated software code, but have not yet performed the clinical comparison studies necessary for validation. Another largely ignored but important technical topic addressed in this application is rigorous evaluation of sources of and methods to correct geometric distortion in MR images. This project has two major goals. The first is to optimize our prototype TBM method and to compare it to other approaches for validation purposes. We will also evaluate methods for correcting geometric distortion in MRI. This validation and testing work is the objective of Aims 1 and 2. The second major goal is to prospectively test the hypothesis that the regional atrophy rate measurement method developed during the technical phase of the project will provide group specific signatures that are characteristic of particular clinical phenotypes, specifically normal aging, AD, and FTD. We will test the hypothesis that TBM regional atrophy rate measures show greater clinical group specificity that global atrophy rate measures. We will also include pathological verification and correlation when possible.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
2P50AG016574-06
Application #
6798071
Study Section
Special Emphasis Panel (ZAG1-ZIJ-7 (J4))
Project Start
2004-05-01
Project End
2009-04-30
Budget Start
2004-05-01
Budget End
2005-04-30
Support Year
6
Fiscal Year
2004
Total Cost
$168,795
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Burke, Shanna L; Maramaldi, Peter; Cadet, Tamara et al. (2018) Decreasing hazards of Alzheimer's disease with the use of antidepressants: mitigating the risk of depression and apolipoprotein E. Int J Geriatr Psychiatry 33:200-211
Brent, Robert J (2018) Estimating the monetary benefits of medicare eligibility for reducing the symptoms of dementia. Appl Econ 50:6327-6340
Qian, Winnie; Fischer, Corinne E; Schweizer, Tom A et al. (2018) Association Between Psychosis Phenotype and APOE Genotype on the Clinical Profiles of Alzheimer's Disease. Curr Alzheimer Res 15:187-194
Sahoo, Aradhana; Bejanin, Alexandre; Murray, Melissa E et al. (2018) TDP-43 and Alzheimer's Disease Pathologic Subtype in Non-Amnestic Alzheimer's Disease Dementia. J Alzheimers Dis 64:1227-1233
Kang, Silvia S; Ebbert, Mark T W; Baker, Kelsey E et al. (2018) Microglial translational profiling reveals a convergent APOE pathway from aging, amyloid, and tau. J Exp Med 215:2235-2245
Pakhomov, Serguei V S; Eberly, Lynn E; Knopman, David S (2018) Recurrent perseverations on semantic verbal fluency tasks as an early marker of cognitive impairment. J Clin Exp Neuropsychol 40:832-840
Gallagher, Damien; Kiss, Alex; Lanctot, Krista et al. (2018) Depression and Risk of Alzheimer Dementia: A Longitudinal Analysis to Determine Predictors of Increased Risk among Older Adults with Depression. Am J Geriatr Psychiatry 26:819-827
Sakae, Nobutaka; Bieniek, Kevin F; Zhang, Yong-Jie et al. (2018) Poly-GR dipeptide repeat polymers correlate with neurodegeneration and Clinicopathological subtypes in C9ORF72-related brain disease. Acta Neuropathol Commun 6:63
Haaksma, Miriam L; Calderón-Larrañaga, Amaia; Olde Rikkert, Marcel G M et al. (2018) Cognitive and functional progression in Alzheimer disease: A prediction model of latent classes. Int J Geriatr Psychiatry 33:1057-1064
Deming, Yuetiva; Dumitrescu, Logan; Barnes, Lisa L et al. (2018) Sex-specific genetic predictors of Alzheimer's disease biomarkers. Acta Neuropathol 136:857-872

Showing the most recent 10 out of 1014 publications